TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024

TScan Therapeutics, Inc.

Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.
Q4 2022 revenue $3.1M, up from $2.9M; FY2022 revenue $13.5M (vs $10.1M in 2021).
Cash and cash equivalents $120.0M as of Dec. 31, 2022; runway into Q2 2024.
Phase 1 hematologic trial for TSC-100/101 expected to enroll all three arms by mid-2023 with preliminary safety/biomarker data.
Solid tumor INDs for T-Plex and two TCRs cleared; initial single-agent TCR data expected by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TScan Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 8, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.